These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 26436350)

  • 21. Some specificities in the management of hyperglycemia in patients with diabetic kidney disease.
    Dragović T; Marinković D; Kiković S; Pejović J; Hajduković Z
    Vojnosanit Pregl; 2016 Sep; 73(9):857-63. PubMed ID: 29320619
    [No Abstract]   [Full Text] [Related]  

  • 22. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC; Borghi C; Consoli A; Volpe M
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidiabetic therapy before and 1 year after discharge for patients manifesting in-hospital hyperglycemia.
    Waddell M; Flanders SJ; Golas A; Zhang Q; Juneja R
    Postgrad Med; 2009 May; 121(3):61-6. PubMed ID: 19491541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoglycaemia in patients with diabetes mellitus and renal impairment.
    Hettige TS; Cooper ME
    Diab Vasc Dis Res; 2017 Mar; 14(2):166-168. PubMed ID: 28128009
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
    Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
    Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of incretin hormones and glucagon in patients with liver disease.
    Junker AE
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Book of Adjustments.
    Scheiner G
    Diabetes Self Manag; 2015; 32(5):30-2. PubMed ID: 26521607
    [No Abstract]   [Full Text] [Related]  

  • 30. Diabetes treatment over age 65: Is worse control really better?
    Bloomgarden Z; Mende C; Einhorn D; Handelsman Y
    J Diabetes; 2017 May; 9(5):428-430. PubMed ID: 28133929
    [No Abstract]   [Full Text] [Related]  

  • 31. Diabetes mellitus: new drugs for a new epidemic.
    Nicholson G; Hall GM
    Br J Anaesth; 2011 Jul; 107(1):65-73. PubMed ID: 21610015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing diabetes in patients with chronic liver disease.
    Khan R; Foster GR; Chowdhury TA
    Postgrad Med; 2012 Jul; 124(4):130-7. PubMed ID: 22913901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of incretin clinical trials.
    Garber AJ; Spann SJ
    J Fam Pract; 2008 Sep; 57(9 Suppl):S10-8. PubMed ID: 18786339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High glucose: an emerging association between diabetes mellitus and cancer progression.
    Supabphol S; Seubwai W; Wongkham S; Saengboonmee C
    J Mol Med (Berl); 2021 Sep; 99(9):1175-1193. PubMed ID: 34036430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
    Bae EJ
    Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
    Freeman JS
    J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S2-6. PubMed ID: 22267300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus.
    Gouni-Berthold I; Hanssen R; Ravarani L; Berthold HK
    Curr Pharm Des; 2017; 23(31):4573-4582. PubMed ID: 28911306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.